Screening, identification, and characterization of an affinity peptide specific to MT1-MMP and its application in tumor imaging.

08:00 EDT 15th April 2019 | BioPortfolio

Summary of "Screening, identification, and characterization of an affinity peptide specific to MT1-MMP and its application in tumor imaging."

Membrane type-1 matrix metalloproteinase (MT1-MMP) plays a crucial role in many physiological and pathological processes, especially in tumor invasion and metastasis. Bioimaging of this key molecule may find wide usage in various applications. MT-loop is a unique sequence of MT1-MMP and locates in the surface of the protein. In our previous studies, AF7p, an affinity peptide that targeting the MT-loop domain of MT1-MMP was identified by screening a phage display (Ph.D.) peptide library. However, the target of AF7p is a synthetic sequence which lacked native conformation of MT-loop region, thus the binding affinity and specificity in reality may not be optimal. In this study, we considered the 3-dimentional (3-D) conformation of the MT-loop area in the MT1-MMP molecule and designed a novel strategy to screen the Ph.D. peptide library. The peptide we obtained showed a better binding affinity to WT-MT1-MMP than AF7p as observed through enzyme-linked immunosorbent assay (ELISA) and biolayer interferometry (BLI). The new peptide labeled and attached MT1-MMP expression cell lines HT1080, and didn't show any toxicity to cells. Furthermore, for in vivo imaging, HT1080 tumor-bearing mice with higher MT1-MMP expression accumulated more Cy5.5-HS7 than mice with MT1-MMP low- expression cell lines A549 at tumor sites, and the half-life of HS7 was longer than that of AF7p, as confirmed by ex vivo imaging of the main organs. These results suggest the feasibility of using subtraction biopanning strategy to screen the affinity peptide targeting MT-loop regions and HS7 is a superior probe for noninvasively imaging MT1-MMP expression in MT1-MMP-positive tumor models. It provide impetus for further studies to use HS7 in early diagnosis of tumors and in peptide-mediated drugs.


Journal Details

This article was published in the following journal.

Name: Bioconjugate chemistry
ISSN: 1520-4812


DeepDyve research library

PubMed Articles [30632 Associated PubMed Articles listed on BioPortfolio]

Recent advances in bio-affinity chromatography for screening bioactive compounds from natural products.

Natural products are one of the most important sources of leading compounds in drug discovery. Until now, rapid screening and identification of biologically active components from natural products rem...

Fluorescent peptide displacement as a general assay for screening small molecule libraries against RNA.

A prominent hurdle in developing small molecule probes against RNA is the relative scarcity of general screening methods. In this study, we demonstrate the application of a fluorescent peptide displac...

Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors.

The role of chemotherapeutic agents in tumor immunotherapy is still controversial. In this study, we test using a TC-1 tumor model whether gemcitabine plus E7 peptide vaccine regimens (E7 peptides+CpG...

Label-free target identification in drug discovery via phenotypic screening.

Phenotypic screening has demonstrated its advantage in the discovery of first-in-class therapeutics, whereas target-based screening has showed strength for follower drugs. Owing to the unbiased nature...

Antibiotic discovery with synthetic fermentation: library assembly, phenotypic screening, and mechanism of action of beta-peptides targeting penicillin-binding proteins.

In analogy to biosynthetic pathways leading to bioactive natural products, synthetic fermentation generates mixtures of molecules from simple building blocks under aqueous, biocompatible conditions, a...

Clinical Trials [14507 Associated Clinical Trials listed on BioPortfolio]

Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors to Define Potential Targets of Targeted and/or Immunomodulatory Therapies

Over the last 10 years, technological advances in molecular biology enabled a more accurate genomic characterization of tumors. For each tumor location, this led to the identification of s...

Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer

Immunotherapy is now considered to be one of promising approaches for treating cancer. Radiation therapy has been to be a cornerstone treatment for unresectable advanced esophageal cancer....

Adjuvant Gemcitabine in Operable Cholangiocellular Carcinoma.

OBJECTIVES Primary objective: The primary objective of the trial is to determine the safety of adjuvant treatment with gemcitabine for a period of 6 months after curative resection...

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

The main purpose of this trial is to investigate the safety and tolerability of NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)in the first-line treatment failed advanced bone ...

NuTech Affinity™ for the Treatment of Chondral Defects

This study was designed to evaluate the long term effectiveness of a product used in knee surgery called Affinity™ Membrane.

Medical and Biotech [MESH] Definitions

The identification of selected parameters in newborn infants by various tests, examinations, or other procedures. Screening may be performed by clinical or laboratory measures. A screening test is designed to sort out healthy neonates (INFANT, NEWBORN) from those not well, but the screening test is not intended as a diagnostic device, rather instead as epidemiologic.

Application of tests and examinations to identify visual defects or vision disorders occurring in specific populations, as in school children, the elderly, etc. It is differentiated from VISION TESTS, which are given to evaluate/measure individual visual performance not related to a specific population.

Testing or screening required by federal, state, or local law or other agencies for the diagnosis of specified conditions. It is usually limited to specific populations such as categories of health care providers, members of the military, and prisoners or to specific situations such as premarital examinations or donor screening.

Identification of individuals who are heterozygous at a GENETIC LOCUS for a recessive PHENOTYPE.

A galanin receptor subtype with high affinity for GALANIN-LIKE PEPTIDE and low affinity for full length GALANIN and galanin peptide fragments.

Quick Search


DeepDyve research library

Relevant Topics

Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

Searches Linking to this Article